• Tezepelumab Trial Does Not Meet Primary Endpoint americanpharmaceuticalreview
    January 08, 2021
    Amgen and AstraZeneca announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticosteroid (OCS) dose, without loss of asthma control, with tezepelumab compared to placebo.
PharmaSources Customer Service